Possibility to treat lung tuberculosis without use of rifampicin in heart transplant recipients--two cases report.
Pulmonary infections remain the leading cause of death in patients after heart transplantation. Lung tuberculosis is more common in transplant recipients than in general population. Two cases of tuberculosis are presented in patients after heart transplantation. Regarding to influence of rifampicin on immunosuppressive therapy, those patients were treated with antimycobacterial drugs except rifampicin. A cure without recurrence can be achieved with a scheme of treatment regimes without rifampicin.
Jastrzebski
Dariusz
D
Dept of Phtisiopneumonology, Silesian School of Medicine, Zabrze, Poland.
Zakliczyński
Michał
M
Kozielski
Jerzy
J
Sioła
Mirosława
M
Dworniczak
Szymon
S
Wojdyła
Agnieszka
A
Zembala
Marian
M
D000328:Adult; D000995:Antitubercular Agents / Q000009:adverse effects / Q000627:therapeutic use*; D016572:Cyclosporine / Q000008:administration & dosage / Q000009:adverse effects; D004305:Dose-Response Relationship, Drug; D004347:Drug Interactions; D004359:Drug Therapy, Combination; D016027:Heart Transplantation / Q000009:adverse effects*; D006801:Humans; D007165:Immunosuppression Therapy / Q000009:adverse effects* / Q000379:methods; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000009:adverse effects; D008297:Male; D012293:Rifampin; D014397:Tuberculosis, Pulmonary / Q000188:drug therapy* / Q000209:etiology*
D000995:Antitubercular Agents; D007166:Immunosuppressive Agents; D016572:Cyclosporine; D012293:Rifampin